Morgan Stanley (NYSE:MS) analyst Matthew Harrison maintained a Hold rating on Editas Medicine (NASDAQ:EDIT) Inc on Wednesday, setting a price target of $64, which is approximately 1.43% below the present share price of $64.93.
Harrison expects Editas Medicine Inc to post earnings per share (EPS) of $0.13 for the fourth quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in Editas Medicine, with an average price target of $51.75.
The analysts price targets range from a high of $69 to a low of $14.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $62.84 million and a net profit of $8.99 million. The company's market cap is $3.86 billion.
According to TipRanks.com, Morgan Stanley analyst Matthew Harrison is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 22.2% and a 62.63% success rate.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.